The decision represents a rare case of a judge overturning a jury verdict and is a major win for Lilly, which argued strenuously that its Emgality drug is substantially different than Anjovy, a drug sold by competitor Teva Pharmaceuticals.
The operation’s primary factory and administration remain in Batesville, where more than 900 people work.
The lawsuit seeks to prevent Inari “from continuing its brazen efforts to steal Corteva’s groundbreaking, patent-protected work,” according to the complaint.
Paul Halverson, the founding dean of the Indiana University Fairbanks School of Public Health, is a longtime advocate for a stronger role for public health across the state.
The solar structures are designed to help generate power for the company and reduce its carbon footprint.
If history is any guide, there will be plenty of high-budget television ads from national and local insurance plans looking to boost their rolls. But the Centers for Medicare & Medicaid Services is cracking down on misleading pitches.
During the last nine years, the cumulative amount of AI investments across the pharma and biotech sectors has increased by almost thirtyfold, to $24.6 billion as of last December.
Paxafe, founded in Milwaukee in 2018 and moved to Indianapolis in 2021, has an AI-risk management platform that predicts when things might go wrong so that its customers can fix them.
Following a $45 million renovation, RayzeBio plans to use the plant to make Actinium 225, a radioisotope used for targeted therapy for cancer.
Researcher Terry Loghmani and two colleagues have developed a medical device they say can help physical therapists monitor the level of pressure they apply to the soft tissue of patients seeking greater mobility and pain relief.
The Indianapolis-based hospital system broke ground Tuesday on the project at 1550 E. County Line Road. The work is expected to take 12 to 15 months to complete.
The Department of Metropolitan Development staff is recommending approval if IU Health explains why it changed several items in the plan, including why it wants to build two surface lots for 291 cars on sites that were previously planned for structures.
A group of about 30 independent medical practices in Indiana, called Indiana Physicians Health Alliance Inc., registered with the state in July as a not-for-profit after nearly two years of organizing.
The two-year-old startup that provides professional services in the health care and life science industries has sharply cut how much it expects to raise in its upcoming initial public offering.
The company, which provides doctors to rural hospitals to staff their emergency rooms and other critical areas, listed liabilities of $18.5 million and assets of just $19,701.
With the new multimillion-dollar conference that kicks off on Tuesday, Indiana is trying to position itself as a globally known innovation hub. And health care will figure prominently on the agenda.
The company, which is developing electrical-nerve stimulation therapies for children, went public this month at an initial price of $6 a share—lower than the range of $7 to $9 a share it announced in February.
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
The IU School of Medicine scored a major coup five years ago when it recruited one of the nation’s top experts in the fast-growing field of regenerative medicine. But the University of Pittsburgh recruited him away this spring.
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
